This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

Jim Cramer Says Investors Should Consider Adding Drug Stocks

Jim Cramer believes the pharmaceutical sector has come full circle and some of the best stocks in the group are ready to move higher.

Jim Cramer Says There's Risk Dow Chemical/DuPont Deal Gets Blocked

Jim Cramer says there is a risk that the Dow Chemical and DuPont deal gets blocked on antitrust concerns.

Jim Cramer Says Facebook Results Bust the Idea That Tech Is Dead

Jim Cramer says Facebook had a remarkable quarter and its earnings report busts the theory that tech is dead.

Jim Cramer: I’m a Huge Backer of Abbott Labs CEO Miles White

Jim Cramer is bullish on Abbott Laboratories' acquisition of St. Jude Medical.


Volume growth shows continued underlying strength.


It delivered the results we would expect from this outstanding management team.


User metrics are better than expected.


Results top expectations in every conceivable metric.


Total payment volume, take rates and updates on 2 growth areas are key.


We believe the social media giant has multiple growth levers to pull and we maintain its shares have long runway ahead of them.

Page 2 of 1758
Top Rated Stocks Top Rated Funds Top Rated ETFs